Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308977231> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4308977231 endingPage "vii215" @default.
- W4308977231 startingPage "vii215" @default.
- W4308977231 abstract "Abstract Glioblastoma (GBM) is the most aggressive adult brain tumor with no effective therapy. Despite advances on its molecular characterization, targeted therapeutics remain out of reach. This lack-of-progress is largely attributed to molecular and spatial heterogeneity and absence of clinically applicable models to guide patient care. Moreover, as standard surgical resection is aimed at contrast-enhancing (CE) tumor, the molecular landscape and treatment response of the remaining non-contrast enhancing (nCE) component is largely unknown despite its active role in tumor progression and local recurrence. Here, we aimed to identify the functional impact of tumor heterogeneity and to explore therapeutic vulnerabilities of both CE and nCE components. Four tumor regions (two CE and two nCE) from each of five GBM patients were collected under neuronavigation. The resulting tissue was subjected to generation of 3D tumor models (a brain tumor initiating-enriched cell line and a spheroid-based mcancer model) with comparable success in both CE and nCE samples. A panel of 25 brain penetrant drugs (alone and in combination) targeting GBM drivers (i.e. RTK/Ras/PI3K, RB/cell cycle, p53/apoptosis, DNA damage repair, transcription addiction) was developed and used to test for therapeutic vulnerabilities. From each tumor region, 4.5 ± 3.7 (average ± SD) different targeting strategies were identified exhibiting at least 70% growth inhibition at Cmax. Drug response heterogeneity was relatively rare, varied among cases, and was independent of tumor enhancement status. To our knowledge, this is the first study to systemically assess treatment response from both CE and nCE patient-derived GBM models. Ongoing studies include comprehensive genome and transcriptome profiling and pathway analysis from these different tumor regions. We postulate that interrogation of molecular landscapes and vulnerability profiles of both CE and nCE tumor regions, will enable us to personalize and prioritize effective targeted interventions for GBM treatment." @default.
- W4308977231 created "2022-11-20" @default.
- W4308977231 creator A5000491993 @default.
- W4308977231 creator A5005212433 @default.
- W4308977231 creator A5019694561 @default.
- W4308977231 creator A5027641707 @default.
- W4308977231 creator A5029294194 @default.
- W4308977231 creator A5031431944 @default.
- W4308977231 creator A5057303099 @default.
- W4308977231 creator A5067072460 @default.
- W4308977231 creator A5090161476 @default.
- W4308977231 date "2022-11-01" @default.
- W4308977231 modified "2023-09-26" @default.
- W4308977231 title "EXTH-28. INTRATUMORAL HETEROGENEITY OF THERAPEUTIC VULNERABILITIES ACROSS ENHANCING AND NON-ENHANCING TUMOR COMPONENTS OF GLIOBLASTOMA: A PARADIGM-SHIFTING PERSONALIZED MEDICINE APPROACH" @default.
- W4308977231 doi "https://doi.org/10.1093/neuonc/noac209.827" @default.
- W4308977231 hasPublicationYear "2022" @default.
- W4308977231 type Work @default.
- W4308977231 citedByCount "0" @default.
- W4308977231 crossrefType "journal-article" @default.
- W4308977231 hasAuthorship W4308977231A5000491993 @default.
- W4308977231 hasAuthorship W4308977231A5005212433 @default.
- W4308977231 hasAuthorship W4308977231A5019694561 @default.
- W4308977231 hasAuthorship W4308977231A5027641707 @default.
- W4308977231 hasAuthorship W4308977231A5029294194 @default.
- W4308977231 hasAuthorship W4308977231A5031431944 @default.
- W4308977231 hasAuthorship W4308977231A5057303099 @default.
- W4308977231 hasAuthorship W4308977231A5067072460 @default.
- W4308977231 hasAuthorship W4308977231A5090161476 @default.
- W4308977231 hasBestOaLocation W43089772311 @default.
- W4308977231 hasConcept C121608353 @default.
- W4308977231 hasConcept C126322002 @default.
- W4308977231 hasConcept C142724271 @default.
- W4308977231 hasConcept C143998085 @default.
- W4308977231 hasConcept C2776194525 @default.
- W4308977231 hasConcept C2779130545 @default.
- W4308977231 hasConcept C2779256057 @default.
- W4308977231 hasConcept C3018028425 @default.
- W4308977231 hasConcept C502942594 @default.
- W4308977231 hasConcept C71924100 @default.
- W4308977231 hasConceptScore W4308977231C121608353 @default.
- W4308977231 hasConceptScore W4308977231C126322002 @default.
- W4308977231 hasConceptScore W4308977231C142724271 @default.
- W4308977231 hasConceptScore W4308977231C143998085 @default.
- W4308977231 hasConceptScore W4308977231C2776194525 @default.
- W4308977231 hasConceptScore W4308977231C2779130545 @default.
- W4308977231 hasConceptScore W4308977231C2779256057 @default.
- W4308977231 hasConceptScore W4308977231C3018028425 @default.
- W4308977231 hasConceptScore W4308977231C502942594 @default.
- W4308977231 hasConceptScore W4308977231C71924100 @default.
- W4308977231 hasIssue "Supplement_7" @default.
- W4308977231 hasLocation W43089772311 @default.
- W4308977231 hasOpenAccess W4308977231 @default.
- W4308977231 hasPrimaryLocation W43089772311 @default.
- W4308977231 hasRelatedWork W1520436343 @default.
- W4308977231 hasRelatedWork W1889256200 @default.
- W4308977231 hasRelatedWork W2029721309 @default.
- W4308977231 hasRelatedWork W2058911076 @default.
- W4308977231 hasRelatedWork W2149694415 @default.
- W4308977231 hasRelatedWork W2229359272 @default.
- W4308977231 hasRelatedWork W2611690426 @default.
- W4308977231 hasRelatedWork W2987996305 @default.
- W4308977231 hasRelatedWork W3108127491 @default.
- W4308977231 hasRelatedWork W4375955343 @default.
- W4308977231 hasVolume "24" @default.
- W4308977231 isParatext "false" @default.
- W4308977231 isRetracted "false" @default.
- W4308977231 workType "article" @default.